Signal transduction

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

Retrieved on: 
星期三, 五月 1, 2024
Conditional sentence, Brain, Drug, Enzyme, Patient, Bone marrow, Acetone, Organelle, Soybean, Inflammation, Methane, Protein, Cell, Laboratory, Mineral, Pregnancy, Blood, Yolk, Health, Apoptosis, Human body, Death, Research, Vitamin, Water, Carbon, Functional food, Phospholipid, Kaifeng, Dietary fiber, Disease, Convalescence, Agonal respiration, Human, Mitochondrion, SISI, Food, Medicine, PC, Golgi, Carbohydrate, Nutrient, Beauty, Signal transduction, Temperature, Ageing, Microsome, Lipid, Cell damage, Malabsorption, Growth, Fats, Phosphorus

Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.

Key Points: 
  • Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.
  • Cells need to continuously obtain nutrients from the external environment to support their normal growth, division and metabolic activities.
  • When cells receive sufficient and balanced nutrients, they can maintain optimal conditions, perform various life activities, and maintain cell health.
  • The layout of the three major fields will create natural active water phospholipids into a super new category in the health industry.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
星期三, 三月 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”

Kanazawa University research: Researchers observe what ubiquitination hinges on

Retrieved on: 
星期三, 一月 10, 2024
American Chemical Society, E6, Nano Letters, DNA, Structural dynamics, E pluribus unum, Tissue, Cervical cancer, Takeda, Signal transduction, Kanazawa University, Enzyme, Fig, Protein, AFM, Observation, E6AP, Cysteine, HPV, Microscope

KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.

Key Points: 
  • KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.
  • Ubiquitination – the addition of the protein ubiquitin - is a key stage in many cell processes, such as protein degradation, DNA repairs, and signal transduction.
  • Using high-speed atomic force microscopy (HS-AFM) and molecular modelling, researchers led by Hiroki Konno and Holger Flechsig at WPI-NanoLSI, Kanazawa University have identified how the mobility of a ubiquitination related enzyme hinge allows ubiquitination to take place.
  • In the 2000s Toshio Ando at Kanazawa University was able to improve the scanning speed to such an extent that moving images could be captured.

Kanazawa University research: Researchers observe what ubiquitination hinges on

Retrieved on: 
星期三, 一月 10, 2024
American Chemical Society, E6, Nano Letters, DNA, Structural dynamics, E pluribus unum, Tissue, Cervical cancer, Takeda, Signal transduction, Kanazawa University, Enzyme, Fig, Protein, AFM, Observation, E6AP, Cysteine, HPV, Microscope

KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.

Key Points: 
  • KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.
  • Ubiquitination – the addition of the protein ubiquitin - is a key stage in many cell processes, such as protein degradation, DNA repairs, and signal transduction.
  • Using high-speed atomic force microscopy (HS-AFM) and molecular modelling, researchers led by Hiroki Konno and Holger Flechsig at WPI-NanoLSI, Kanazawa University have identified how the mobility of a ubiquitination related enzyme hinge allows ubiquitination to take place.
  • In the 2000s Toshio Ando at Kanazawa University was able to improve the scanning speed to such an extent that moving images could be captured.

Michael J. Fox Foundation for Parkinson's Research Honors Dario Alessi, PhD, with the Robert A. Pritzker Prize for Leadership in Parkinson's Research

Retrieved on: 
星期一, 十一月 13, 2023
School, Genetics, ASAP, University of Dundee, Research, Phosphorylation, Parkinson's disease, Biology, Alessi, Disease, Science, History, Student, MJFF, Mentorship, Ubiquitin, Pritzker Architecture Prize, University, LRRK2, Doctor of Philosophy, Mutation, Signal transduction, Pharmaceutical industry, PD

The prize recognizes researchers who make exceptional contributions to Parkinson's disease (PD) research and are committed to mentoring the next generation of Parkinson's scientists.

Key Points: 
  • The prize recognizes researchers who make exceptional contributions to Parkinson's disease (PD) research and are committed to mentoring the next generation of Parkinson's scientists.
  • Padmanabhan presented the prize to Alessi at the Foundation's Research Roundtable event in New York City on November 11, 2023.
  • The Robert A. Pritzker Prize for Leadership in Parkinson's Research, awarded annually by MJFF since 2011, was established by Karen Pritzker, daughter of Robert A. Pritzker, and her late husband, investor Michael Vlock.
  • Watch the "Robert A. Pritzker Prize for Leadership in Parkinson's Research: Inspiring Hope for a World Free from Parkinson's" video: https://www.youtube.com/watch?v=KkaefcwfE4Q

Totus Medicines Appoints John Maraganore to Scientific Advisory Board

Retrieved on: 
星期四, 十月 19, 2023
Signal transduction, China Executive Leadership Academy in Pudong, Ioan Totu, RNA interference, Therapy, RNA, Alnylam Pharmaceuticals, BIO, PI3K, Disease, Biotechnology Innovation Organization, Drug discovery, Cancer, John Maraganore, Patient, SAB, United States Air Force Scientific Advisory Board, Pharmaceutical industry

EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Totus Medicines , the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, is pleased to announce the appointment of John Maraganore, Ph.D., to the company's Scientific Advisory Board (SAB).

Key Points: 
  • EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Totus Medicines , the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, is pleased to announce the appointment of John Maraganore, Ph.D., to the company's Scientific Advisory Board (SAB).
  • Maraganore brings over three decades of experience and most recently served as the founding CEO and director of Alnylam Pharmaceuticals.
  • Maraganore remains a member of the Alnylam Scientific Advisory Board.
  • "It's an honor to have John Maraganore join as the newest member of our Scientific Advisory Board," said Totus CEO and co-founder Neil Dhawan, Ph.D. "John brings valuable experience in advancing therapeutics from discovery to commercialization at a time when our first program is rapidly advancing through clinical trials.

Pusan National University Researchers Identify Peptides for Pollen Tube Growth in Rice

Retrieved on: 
星期五, 八月 11, 2023
Male, CRISPR, Breeding, Agriculture, Pusan National University, Oryza, Pollen tube, Double, Pollen, Research, Signal transduction, Fertilisation, Integrated pest management, Reproduction, Peptide, Assistant, Grain, Germination, Plant, Kyung Hee University, Journal, Reactive oxygen species, Fertility, John, Growth, Biology

BUSAN, South Korea, Aug. 11, 2023 /PRNewswire/ -- Double fertilization is a complex mechanism in flowering plants, wherein two sperm cells fuse with the embryo sac. To achieve this, pollens released from anthers must interact with the plant's stigma, hydrate, and germinate into pollen tubes. Thus, pollen tube germination and elongation are crucial for double fertilization, which, in turn, influences the grain yield of crop plants.

Key Points: 
  • Thus, pollen tube germination and elongation are crucial for double fertilization, which, in turn, influences the grain yield of crop plants.
  • Studies have shown that RALFs play an important role in pollen tube growth.
  • D. student Eui-Jung Kim from Kyung Hee University, has identified and characterized two RALF peptides in rice (Oryza sativa).
  • In addition, the effect seemed to be dose-dependent because the OsRALFs inhibited pollen tube germination and growth at higher concentrations.

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Retrieved on: 
星期二, 八月 8, 2023
Molecule, Neuron, Rat, DMT, CSE, DMT: The Spirit Molecule, Depression, Neuroplasticity, Stroke, Clinical trial, Penile spines, AGN, Pharmacokinetics, Brain, Biomarker, Signal transduction, Plasma, Ethics, Patient, Growth, Diagnosis, BDNF, Death, Imperial College London, CHDR, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.
  • The Phase 2 human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • Algernon consultant Dr. Rick Strassman, DMT research pioneer and author of the books DMT: The Spirit Molecule and The Psychedelic Handbook commented: “I am encouraged by the results of Algernon’s Phase 1 study in which a prolonged infusion of DMT achieved the desired pharmacokinetics.
  • “We are investigating DMT as a potential new therapeutic treatment that could have a positive impact on ischemic stroke patients worldwide.”

InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

Retrieved on: 
星期三, 七月 5, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Clinical trial, Cancer, Psoriasis, Quality of life, SAD, Signal transduction, BTK, Incidence, SSE, HKEX, Patient, TYK2, MAD, Autoimmunity, Safety, Inflammation, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor ICP-488 in China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor ICP-488 in China.
  • The ongoing study with psoriasis patients aims to evaluate the safety and efficacy of ICP-488 in patients with moderate-to-severe psoriasis.
  • ICP-488 is a potent and selective TYK2 allosteric inhibitor, which is developed for the treatment of psoriasis and other autoimmune diseases.
  • InnoCare is developing autoimmune therapeutics with global frontier targets through B-cell and T-cell pathways, including orelabrutinib (BTK inhibitor), ICP-332 (TYK2-JH1 inhibitor), ICP-488 (TYK2-JH2 inhibitor), and more.

EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients

Retrieved on: 
星期四, 六月 8, 2023
National Institute on Drug Abuse, Hebrew University of Jerusalem, Al-Quds, Cancer, Quality of life, Research, Signal transduction, Rash, Patient, EGFR, Hadassah Medical Center, NGT, Financial toxicity, Skin, Growth factor, Pharmaceutical industry

JERUSALEM, June 8, 2023 /PRNewswire/ -- Hadasit, and Yissum, has spun off EMRIS Pharma in collaboration with NGT Healthcare2 VC.  EMRIS Pharma is pioneering novel small molecule-based topical compounds that can improve both quality of life and treatment compliance for cancer patients. Based on over ten years of research collaboration by the founders, Dr. Sharon Merims, a senior dermatologist specializing in dermato-oncology at the Hadassah Medical Center, and Professor Ofra Benny from the Institute for Drug Research at the Hebrew University of Jerusalem, and with the support of NGT Healthcare2 VC, the company's first product aims to treat the skin toxicities caused by EGFRi (Epidermal Growth Factor Receptor inhibitors). Many of the molecularly targeted agents used in current cancer treatments, particularly those interfering with signal transduction EGFRi and small molecule tyrosine kinase inhibitors, are associated with papulopustular skin rash. This rash is observed in ~90% of patients receiving EGFR-targeted monoclonal antibodies, and often impacts the patient's quality of life, and the ability to continue the cancer treatment. Dr. Merims will serve as EMRIS Pharma's Chief Scientific Officer, and Professor Benny as the company's Chief Technology Officer.

Key Points: 
  • EMRIS Pharma is pioneering novel small molecule-based topical compounds that can improve both quality of life and treatment compliance for cancer patients.
  • This rash is observed in ~90% of patients receiving EGFR-targeted monoclonal antibodies, and often impacts the patient's quality of life, and the ability to continue the cancer treatment.
  • Their novel approach to managing skin toxicities caused by EGFR inhibitors has the potential to significantly improve the quality of life for cancer patients and increase treatment compliance.
  • We believe that EMRIS Pharma's innovative research and development will lead to a brighter future for cancer patients, and we look forward to supporting their mission."